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Abstract 
Background: Gross target volume of primary tumor (GTV‑P) is very important for the prognosis prediction of 
patients with nasopharyngeal carcinoma (NPC), but it is unknown whether the same is true for locally advanced NPC 
patients treated with intensity‑modulated radiotherapy (IMRT). This study aimed to clarify the prognostic value of 
tumor volume for patient with locally advanced NPC receiving IMRT and to find a suitable cut‑off value of GTV‑P for 
prognosis prediction.
Methods: Clinical data of 358 patients with locally advanced NPC who received IMRT were reviewed. Receiver oper‑
ating characteristic (ROC) curves were used to identify the cut‑off values of GTV‑P for the prediction of different end‑
points [overall survival (OS), local relapse‑free survival (LRFS), distant metastasis‑free survival (DMFS), and disease‑free 
survival (DFS)] and to test the prognostic value of GTV‑P when compared with that of the American Joint Committee 
on Cancer T staging system.
Results: The 358 patients with locally advanced NPC were divided into two groups by the cut‑off value of GTV‑P 
as determined using ROC curves: 219 (61.2%) patients with GTV‑P ≤46.4 mL and 139 (38.8%) with GTV‑P >46.4 mL. 
The 3‑year OS, LRFS, DMFS, and DFS rates were all higher in patients with GTV‑P ≤46.4 mL than in those with 
GTV‑P > 46.4 mL (all P < 0.05). Multivariate analysis indicated that GTV‑P >46.4 mL was an independent unfavorable 
prognostic factor for patient survival. The ROC curve verified that the predictive ability of GTV‑P was superior to that of 
T category (P < 0.001). The cut‑off values of GTV‑P for the prediction of OS, LRFS, DMFS, and DFS were 46.4, 57.9, 75.4 
and 46.4 mL, respectively.
Conclusion: In patients with locally advanced NPC, GTV‑P >46.4 mL is an independent unfavorable prognostic indi‑
cator for survival after IMRT, with a prognostic value superior to that of T category.
Keywords: Nasopharyngeal carcinoma, Intensity‑modulated radiotherapy, Gross target volume of primary tumor, 
Prognosis
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Background
According to the report of Wei et al. [1], 41,503 new can-
cer cases and 20,058 cancer deaths were attributed to 
nasopharyngeal carcinoma (NPC) in China in 2010. Most 
cases of treatment failure occurred in patients with local 
or regional advanced tumors. Currently, the prognosis 
prediction and treatment decision are primarily made on 
the basis of clinical stage. As comprehensive treatment 
including IMRT is widely used, clinical stage alone can-
not predict prognosis accurately. Fletcher and Million [2] 
proposed that tumor volume is the most direct indica-
tor of the number of clones needed to be killed among 
the cancer cells, which represents the concept of tumor 
burden. In addition, large tumors often cause lack of oxy-
gen, radiation resistance, and poor local control. Stanley 
et  al. [3] demonstrated that no hypoxic fraction could 
be detected in 0.5  mm3 pulmonary tumors. However, 
hypoxia appears with an increase in tumor volume [3], 
and hypoxic tumor cells have poorer reaction to radia-
tion than oxygen-enriched tumor cells [4]. Experiments 
have demonstrated that it is necessary to increase the 
radiation dose to overcome radiation resistance result-
ing from hypoxic tumor cells [5]. Sze et  al. [6] found 
that with every 1  cm3 increase in tumor volume, local 
failure increased by 1%. Thus, the greater the volume is, 
the higher the radiation dose requires and the worse the 
prognosis is. In fact, the staging systems of lung cancer, 
oral cancer, and other cancers already contain informa-
tion about tumor volume.
So far, tumor volume has not been included in the clin-
ical staging of NPC, but clinical trials have shown that in 
patients receiving conventional radiotherapy [7] or inten-
sity-modulated radiotherapy (IMRT) [8], tumor volume 
is closely related to the prognosis of NPC. Even in the 
locally recurrent NPC, it was reported that the evaluation 
of prognosis was improved if tumor volume is incorpo-
rated into the staging [9]. However, the cut-off value of 
tumor volume that predicts a poor prognosis has been 
reported inconsistently [5, 6, 10, 11]. This is the main rea-
son why tumor volume had not been considered in the 
clinical staging of NPC yet.
Tumor volume overlaps between tumors at different 
T categories; on the other hand, for tumors in the same 
T category, especially T3/T4 tumors, their volumes vary 
widely. Poor prognosis has been commonly reported to 
relate with a tumor volume greater than 50–60 mL [10–
13]. However, the volume of T1/T2 tumors rarely reaches 
50–60 mL. In addition, Chua et al. [14] reported that in 
patients with early-stage NPC, tumor volume was not an 
independent prognostic factor. Therefore, we hypothe-
sized that tumor volume mainly affected the prognosis of 
locally advanced NPC, and we only selected patients with 
locally advanced NPC to assess whether tumor volume 
can be used to predict prognosis of patients receiving 
IMRT. In addition, cut-off values of tumor volume for the 
prediction of different endpoints were determined.
Patients and methods
Patient selection
Patients with newly diagnosed, non-metastatic, locally 
advanced NPC (T3-4N0-3M0) who received IMRT 
between August 2008 and December 2011 at Xiangya 
Hospital of Central South University (Changsha, Hunan, 
China) were selected. Exclusion criteria were as follows: 
incomplete baseline magnetic resonance imaging (MRI) 
or computed tomography (CT) scan information, meta-
static or recurrent tumors, early-stage NPC, receiving 
conventional radiotherapy. The study was approved by 
the Ethics Committee of Xiangya Hospital of Central 
South University (approval number 201111086).
Imaging and clinical staging
Simulation CT and MRI were required before treatment. 
When a simulation MRI was performed, patients were 
required to use the same pillow for simulation CT to 
maintain basically the same position as that in CT scan-
ning. The layer thickness for both MRI and CT scans was 
3 mm, from 2 cm above the sella turcica to 2 cm below the 
lower edge of the clavicle. Automatic image fusion was 
carried out according to the osseous marks. In addition 
to CT or MRI examination of the nasopharynx and neck, 
complete medical history-taking, physical examination, 
chest X-ray radiography and/or CT (all patients with N3 
disease underwent a chest CT), B-ultrasound scan of the 
abdomen and neck, whole-body bone scan, and routine 
laboratory analysis were performed before treatment. To 
reduce subjectivity, all patients were restaged according 
to the 7th edition of the American Joint Committee on 
Cancer (AJCC) Staging System for NPC. The MRI images 
for each patient were independently reviewed by two 
senior clinicians from the Departments of Radiology and 
Oncology. Controversial cases must reach an agreement 
through the discussion of staff from the Department of 
Radiotherapy.
Tumor volume measurement
The targets were delineated on the MRI and CT fused 
images. The gross target volume of primary tumor of the 
nasopharynx (GTV-P) was manually outlined accord-
ing to the postcontrast axial T1-weighted images of 
immobilization MRI and then errors caused by position 
changes on the enhanced images of immobilization CT 
were corrected by senior clinicians from the Department 
of Oncology. The involved retropharyngeal lymph nodes 
were included as part of the GTV-P, as the discrimination 
of the retropharyngeal lymph nodes from primary tumor 
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remains difficult in NPC patients. In addition, the GTV-P 
of NPC patients receiving neoadjuvant chemotherapy 
was delineated before neoadjuvant chemotherapy. The 
GTV-P was calculated using the treatment planning sys-
tem (TPS, Varian Medical System, Inc., Palo Alto, CA, 
USA) by the summation-of-area technique, which multi-




All patients underwent IMRT. The specific target was 
defined as described in our previous studies [15]. The 
prescribed doses were 66.0–75.9 Gy for the PTVnx [the 
planning target volume (PTV) covering the GTV-P with 
additional 3–5 mm margin], 70.0–72.6 Gy for the GTV of 
positive lymph nodes (GTVnd), 59.4–64.0 Gy for PTV1 
[the PTV covering the clinical target volume 1 (CTV1, 
the high-risk area that included a 5–10  mm extension 
around the GTV-P and other high-risk regions and high-
risk lymphatic drainage areas) with additional 3 mm mar-
gin], and 50.0–54.0 Gy for PTV2 [the PTV covering the 
CTV2 (the low-risk lymphatic drainage area, including 
the cervical lymphatic drainage area that was not covered 
in CTV1) with additional 3  mm margin]. The irradia-
tion to the PTV2 was administered in 28 fractions, and 
the irradiation to other volumes was in 33 fractions. All 
patients were treated with simultaneously modulated 
accelerated radiotherapy once a day for 5 days per week. 
Dose constraints for critical tissue structures and plan 
evaluation were as defined in our previous study [16]. 
Therein, dose constraints to critical normal structures 
were as follows: the doses to the brainstem, optic nerves, 
and chiasm cannot exceed 54  Gy, or the dose to 1% of 
the planning organ-at-risk volume (PRV) cannot exceed 
60 Gy; the dose to the spinal cord cannot exceed 45 Gy, 
or the dose to 1 mL of the PRV cannot exceed 50 Gy; the 
dose to the temporal lobes cannot exceed 60 Gy, or the 
dose to 1% of the PRV cannot exceed 65 Gy. Dose con-
straints for the brainstem and spinal cord had a higher 
priority than GTV or CTV coverage; however, dose con-
straints for other normal structures were considered to 
have lower priority than GTV or CTV coverage.
Chemotherapy
Chemotherapy was part of the treatment plan for all 
patients; the patients who were unwilling to receive 
chemotherapy or could not tolerate chemotherapy had 
not undergone chemotherapy. Neoadjuvant chemo-
therapy was administered to downsize bulky tumors. 
At the end of radiotherapy, adjuvant chemotherapy was 
administered to the patients with N2/N3 disease and 
those with residual disease detected by MRI or physical 
examination. Neoadjuvant chemotherapy or adjuvant 
chemotherapy consisted of cisplatin (75–80  mg/m2, 3-h 
intravenous infusion) plus 5-fluorouracil (4.0 g/m2, 120-h 
pumping) or taxanes (135–175  mg/m2, 3-h intravenous 
infusion) every 3 weeks for two or three cycles. Concur-
rent chemotherapy consisted of cisplatin (80 mg/m2, 3-h 
intravenous infusion) every 3  weeks. IMRT was given 
1–2  weeks after neoadjuvant chemotherapy, and adju-
vant chemotherapy was given 3–4 weeks after IMRT.
Follow‑up
Follow-up was measured from the first day of treat-
ment to the last follow-up date (Jan 2015) or the day of 
patient’s death. After radiotherapy, follow-up examina-
tions were conducted every 3 months in the first 2 years, 
every 6  months in the following 3  years, and annually 
thereafter. The overall survival (OS), local relapse-free 
survival (LRFS), distant metastasis-free survival (DMFS), 
and disease-free survival (DFS) were defined as described 
in our previous study [13]. Relapse was defined as the 
appearance of tumor after the tumor was undetectable 
for at least 1 month. The duration of OS was calculated 
from the day of radiotherapy completion to the day of 
death or the last follow-up; LRFS, to the day of local or 
regional relapse; DMFS, to the day of tumor metastasis; 
and DFS, to the day of tumor relapse, distant metastasis, 
or death.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences version 17.0 (SPSS 
Inc., Chicago, IL, USA). The normality test of tumor 
volume was completed first, then Mann–Whitney non-
parametric tests were used to analyze the differences of 
tumor volume between T3 and T4 NPC or between dif-
ferent survival statuses. Actuarial rates were calculated 
using the Kaplan–Meier method, and differences were 
compared using the log-rank test. Multivariate analysis 
with the Cox proportional hazards model was used to test 
for independent significance by backward elimination 
of insignificant explanatory variables. Receiver operat-
ing characteristic (ROC) curves were used to identify the 
cut-off values for different endpoints (OS, LRFS, DMFS, 
and DFS). The areas under the ROC curve (AUC) were 
used to assess the prognostic value of GTV-P compared 
with the American Joint Committee on Cancer (AJCC) T 
category. The criterion for statistical significance was set 
at α = 0.05 and P values were based on two-sided tests.
Results
General clinical characteristics
Among the 1050 NPC patients who underwent IMRT in 
our hospital between 2008 and 2011, 358 were eligible for 
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the analysis. Till the final follow-up in Jan 2015, median 
follow-up period was 45  months (range, 3–78  months). 
Twelve patients were lost to follow-up, and the remain-
ing 346 patients were eligible for survival analysis. The 
median age was 46 years (range, 17–82 years). The clini-
cal characteristics of the patients are summarized in 
Table 1.
Treatment outcomes
Of the 346 patients with follow-up data, 22 (6.4%) 
developed local relapse, 55 (15.9%) developed distant 
metastasis, and 9 (2.6%) developed relapse plus distant 
metastasis. There were 64 (18.5%) deaths: 49 patients died 
of tumor relapse and metastasis, 10 of tumor-associated 
complications, 1 of gastrointestinal bleeding, and 4 of 
unknown causes.
Distribution characteristics of GTV‑P in locally advanced 
NPC
The overall distribution of GTV-P in 358 patients with 
locally advanced NPC was non-normal (P > 0.10) (Fig. 1). 
The median value of GTV-P was 37.9 mL, ranging from 
5.9 to 204.8 mL, with a 25th percentile (p25) of 22.3 mL, 
and 75th percentile (p75) of 56.0 mL.
The median GTV-P was 25.3  mL (interquartile range, 
15.4–34.5  mL) in patients with T3 tumors and 49.2  mL 
(interquartile range, 25.9–62.9  mL) in patients with T4 
tumors. The value of GTV-P ranged widely in patients 
with the same T category, and considerable overlap of 
GTV-P was observed in tumors with different T catego-
ries (Fig. 2a).
Figure  2b shows a significant difference in median 
GTV-P under different survival situations (P  <  0.001, 
Kruskal–Wallis test). The median GTV-P was the largest 
in patients who developed relapse and distant metastasis 
(81.5  mL; interquartile range, 54.6–108.0  mL), followed 
by patients who had distant metastasis (60.7  mL; inter-
quartile range, 29.3–77.3  mL), relapse (52.5  mL; inter-
quartile range, 33.9–66.8  mL), unexplained deaths 
(48.1  mL; interquartile range, 32.1–63.6  mL), compli-
cation-associated deaths (47.8  mL; interquartile range, 
27.6–58.6 mL), no relapse or distant metastasis (39.9 mL; 
interquartile range, 21.0–53.1 mL), and those lost to fol-
low-up (36.1 mL; interquartile range, 14.7–56.2 mL).
Cut‑off values of GTV‑P for different endpoints and their 
sensitivity and specificity
The cut-off values of GTV-P calculated using the ROC 
curves were 46.4  mL for OS prediction with a sensitiv-
ity of 59.4% and a specificity of 66.0%; 46.4 mL for DFS 
prediction with a sensitivity of 56.6% and a specificity 
of 66.9%; 57.9  mL for LRFS prediction with a sensitiv-
ity 62.5% and a specificity 77.9%; and 75.4 mL for DMFS 
prediction with a sensitivity of 36.4% and a specificity of 
91.8% (Table 2).
Survival of locally advanced NPC patients with different 
GTV‑P and T categories
Patients were divided into two groups according to the 
cut-off value of GTV-P (≤46.4 or >46.4 mL). The 3-year 
survival rates are shown in Table  3. The OS, LRFS, 
DMFS, and DFS were significantly longer in patients with 
GTV-P ≤46.4  mL than in those with GTV-P  >46.4  mL 
(P < 0.05) (Fig. 3a–d). The OS and LRFS were similar in 
patients with T3 and T4 tumors (both P > 0.05), whereas 
the DMFS and DFS were significantly longer in patients 
with T3 tumors than in those with T4 tumors (P = 0.035 
Table 1 Clinical characteristics of  the 358 patients 
with locally advanced nasopharyngeal carcinoma (NPC)
WHO World Health Organization, NACT neoadjuvant chemotherapy
a The 7th American Joint Committee on Cancer (AJCC) staging system was used 
for T and N classification
Characteristic No. of patients Percentage (%)
Age (years)
 <50 232 64.8
 ≥50 126 35.2
Sex
 Male 255 71.2
 Female 103 28.8
T categorya
 T3 64 17.9
 T4 294 82.1
N categorya
 N0 66 18.4
 N1 113 31.6
 N2 118 33.0
 N3 61 17.0
Tumor volume (mL)
 ≤46.4 219 61.2
 >46.4 139 38.8
WHO histological type
 I 25 7.0
 II–III 333 93.0
Chemotherapy
 None 21 5.9
 Concurrent or NACT or adjuvant 47 13.1
 Concurrent + NACT 39 10.9
 Concurrent + adjuvant 10 2.8
 NACT + adjuvant 92 25.7
 NACT + concurrent + adjuvant 149 41.6
Prescribed total dose (Gy)
 <73.92 111 31.0
 ≥73.92 247 69.0
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and P  =  0.033) (Fig.  3e–h). To analyze the prognos-
tic value of GTV-P in patients with the same T cate-
gory, T3 tumors were subclassified as T3V1 (T3 tumors 
with GTV-P  ≤46.4  mL) and T3V2 tumors (T3 tumors 
with GTV-P  >46.4  mL), and T4 tumors were subclas-
sified as T4V1 (T4 tumors with GTV-P ≤46.4  mL) and 
T4V2 tumors (T4 tumors with GTV-P  >46.4  mL). The 
OS, LRFS, DMFS, and DFS were all significantly longer 
in patients with T4V1 tumors than in those with T4V2 
tumors (all P  <  0.05), whereas no significant differences 
in survival were observed between patients with T3V1 
and T3V2 tumors (all P > 0.05) (Fig. 3i–l).
Prognostic values of GTV‑P and T category in locally 
advanced NPC
Table  4 shows the results of multivariate analyses 
adjusted for age, sex, pathologic type, 7th AJCC T cat-
egory, N category, chemotherapy, and radiation dose, 
which were considered to have significant effects on 
prognosis. GTV-P was an independent prognostic fac-
tor for OS (hazard ratio [HR] = 2.463, P = 0.001), LRFS 
(HR = 2.798, P = 0.048), DMFS (HR = 2.620, P = 0.001), 
and DFS (HR  =  2.335, P  <  0.001). Other independent 
prognostic factors were age and N category for OS, age 
for LRFS, N category for DMFS, and age and N category 
for DFS.
ROC curves show that the prognostic value of GTV-P 
for OS prediction was better than that of T category 
(AUC: 0.547 vs. 0.627; P < 0.001) (Fig. 4).
Discussion
It is well known that tumor volume is a very important 
prognostic factor in NPC, and tumor volume increases 
with tumor progression. The more advanced the dis-
ease is, the larger the tumor volume is, and the greater it 
affect prognosis. The present study showed that GTV-P 
Fig. 1 Histogram of the gross target volume of primary tumor (GTV‑
P) in patients with locally advanced nasopharyngeal carcinoma (NPC)
Fig. 2 Box plot of GTV‑P in patients with locally advanced NPC. a GTV‑P of patients with T3 and T4 tumors. The 7th American Joint Committee on 
Cancer (AJCC) staging system was used for T classification. b GTV‑P of patients with different survival statuses
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varied greatly in locally advanced NPC patients, ranging 
from 5.9 to 204.8  mL, and significant differences were 
seen between T3 and T4 tumors. In addition, GTV-P 
was associated with prognosis in our study. Patients who 
developed relapse and metastasis had the largest GTV-P 
(81.5 ± 10 mL), followed by those developed metastasis 
(60.7 ± 6.5 mL), those developed relapse (52.5 ± 7.7 mL), 
and others (P  <  0.001). Similar to our results, Li et  al. 
[8] and Feng et  al. [17] reported that the GTV-P was 
significantly associated with local failure. Wu et  al. [18] 
reported that the GTV-P was associated with lymph 
node metastasis (P   <   0.001) and post-treatment distant 
metastasis (P  =  0.007).
In our study, the OS and LRFS were not significantly 
different in patients with different T categories. However, 
when we select the cut-off value of GTV-P of 46.4  mL 
according to ROC curves, the 3-year OS, LRFS, DMFS, 
and DFS rates were significantly higher in patients with 
GTV-P ≤46.4 mL than in patients with GTV-P >46.4 mL 
(Table 3). In multivariate analyses, GTV-P was an inde-
pendent factor for OS, LRFS, DMFS, and DFS predic-
tion. Furthermore, when patients with T4 NPC were 
divided into two subgroups according to tumor volume, 
the 3-year OS, LRFS, DMFS, and DFS rates were sig-
nificantly higher in patients with T4V1 tumors than in 
patients with T4V2 tumors. However, these differences 
were not statistically significant between the patients 
with T3V1 and T3V2 tumors, and the too small num-
ber of patients may account for this result. These results 
suggest that tumor volume may be more useful for pre-
dicting prognosis than T category in locally advanced 
NPC patients receiving IMRT. Similar to our results, 
Table 2 Sensitivity, specificity, and  AUC of  different cut-off values of  GTV-P for  survival prediction in  the 346 patients 
with locally advanced NPC
Twelve patients were lost to follow-up and, thus, were not included in the survival analysis
AUC area under the curve, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
– AUC of inferior cut-off value for the endpoint was not calculated
End‑point GTV‑P cut‑off value
46.4 mL 57.9 mL 75.4 mL
Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC
OS 59.4 66 0.662 39.1 79.4 – 26.6 90.4 –
LRFS 50 62 – 62.5 77.9 0.702 25 88 –
DMFS 61.8 65.6 – 40 79.2 – 36.4 91.8 0.668
DFS 56.6 66.9 0.668 37.5 80.1 – 26.5 91.6 –
Table 3 The 3-year survival rates of locally advanced NPC patients with different GTV-P and T categories
OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
a T3 tumors were subclassified as T3V1 (T3 tumors with GTV-P ≤46.4 mL) and T3V2 tumors (T3 tumors with GTV-P >46.4 mL)
b T4 tumors were subclassified as T4V1 (T4 tumors with GTV-P ≤46.4 mL) and T4V2 tumors (T4 tumors with GTV-P >46.4 mL)
Variable OS (%) P value LRFS (%) P value DMFS (%) P value DFS (%) P value
GTV‑P (mL) <0.001 0.015 <0.001 <0.001
 ≤46.4 90.5 96.6 90.2 85.3
 >46.4 75.5 90.9 74.5 67.5
T category 0.105 0.667 0.035 0.033
 T3 89.6 93.2 93.2 88.1
 T4 83.7 94.7 82.8 76.4
Sub‑T3a 0.345 0.158
 T3V1 90.7 94.5 94.5 89.1
 T3V2 75.0 75.0 75.0 75.0
Sub‑T4b <0.001 0.014 <0.001 <0.001
 T4V1 90.4 97.2 89.4 84.0
 T4V2 75.6 91.5 74.5 67.3
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previous studies in either the early conventional radio-
therapy period [11, 12, 19, 20] or the IMRT era [10, 13, 
21–24] suggested that tumor volume was an independ-
ent prognostic factor for NPC. Furthermore, the impact 
of GTV-P on prognosis is greater than that of T category 
[11]. However, the previous studies selected patients 
with NPC of all stages. Because the variation of GTV-P 
is relatively small in T1 and T2 tumors, the impact of 
GTV-P on prognosis of early-stage NPC may not be 
as significant as that of locally advanced NPC. What if 
locally early and locally advanced NPC were examined 
separately? Chua et  al. [14] analyzed 116 patients with 
stage I and stage II NPC, using CT for target delinea-
tion. Tumor volume was calculated using the area sum 
method. Their results revealed that tumor volume was 
not an independent prognostic factor for patients with 
early-stage NPC who underwent radiotherapy alone. 
The main reasons may be that the methods of tumor 
delineation and volume calculation were not very accu-
rate and that the tumor volume itself (median, 12.6 mL) 
and its variation in patients with early-stage NPC were 
relatively small. So far, few studies had excluded patients 
with T1 and T2 NPC when evaluating the prognos-
tic value of GTV-P. We were able to retrieve only one 
study by Chang et al. [25] who reported that the primary 
tumor volume range was 8.0–131.8  mL for T3 tumors 
and 6.7–223.1 mL for T4 tumors and that large primary 
tumor volume was significantly associated with short 
disease-specific survival (P < 0.001), whereas the T cate-
gory carried no prognostic significance (P = 0.43). These 
results are very similar to our results. However, the 
threshold of volume in Chang’s study was determined on 
the basis of clinical experience rather than a ROC analy-
sis. In addition, their patients underwent conventional 
Fig. 3 Survival curves of locally advanced NPC patients with different GTV‑P and T categories. Patients with different GTV‑P had significant differ‑
ences in overall survival (OS) (a), local relapse‑free survival (LRFS) (b), distant metastasis‑free survival (DMFS) (c), and disease‑free survival (DFS) (d). 
Patients with different T categories were not different in OS (e) or LRFS (f), but had significant differences in DMFS (g) and DFS (h). T3 tumors were 
subclassified as T3V1 (T3 tumors with GTV‑P ≤46.4 mL) and T3V2 tumors (T3 tumors with GTV‑P >46.4 mL); T4 tumors were subclassified as T4V1 
(T4 tumors with GTV‑P ≤46.4 mL) and T4V2 tumors (T4 tumors with GTV‑P >46.4 mL). Significant differences in OS (i), LRFS (j), DMFS (k), and DFS (l) 
were observed between patients with T4V1 and T4V2 tumors, but not between patients with T3V1 and T3V2 tumors
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radiotherapy, which was different from IMRT in terms of 
target delineation and tumor volume calculation.
The cut-off values of GTV-P vary among different stud-
ies, and this is the main reason that tumor volume has 
not been included in the clinical staging. In our study, 
evaluated with ROC analysis, the cut-off values of GTV-P 
were 46.4  mL for OS and DFS prediction, 57.9  mL for 
LRFS prediction, and 75.4  mL for DMFS prediction. A 
greater cut-off value of tumor volume was associated 
with a higher specificity and a lower sensitivity (Table 2). 
GTV-P > 46.4 mL was proved to be an independent unfa-
vorable factor for OS, LRFS, DMFS, and DFS predication 
through multivariate analysis. Chen et al. [10] studied the 
prognostic value of tumor volume for patients with stage 
I–IVb NPC who underwent IMRT. Their grouping infor-
mation was as follows: V1  <  15.65, V2  =  15.65–24.25, 
V3  =  24.25–50.55, and V4  >  50.55  mL; the 5-year OS 
rates were 88.5%, 83.3%, 82.4% and 54.5%, respectively 
(P = 0.014), noting that the survival rate decreased signif-
icantly in the V4 group. Meanwhile, Lee et al. [11], Shen 
et al. [12], and Chen et al. [13] also suggested that when 
GTV-P was greater than 50–60  mL, the prognosis was 
getting worse accordingly. The cut-off value of GTV-P 
for predicting OS and DFS in our study was close to that 
Table 4 Multivariate analysis of prognostic factors for locally advanced NPC
HR hazard ratio, CI confidence interval, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
P values were calculated using an adjusted Cox proportional hazards model
Endpoint Variable Regression coef‑
ficient
Standard error P value HR 95% CI
OS Age (<50 vs. ≥50 years) 0.793 0.251 0.002 2.209 1.350–3.616
T category (T3 vs. T4) 0.134 0.452 0.766 1.144 0.472–2.775
N category (N0 vs. N1 vs. N2 vs. N3) 0.364 0.133 0.006 1.439 1.108–1.868
Sex (male vs. female) −0.168 0.278 0.547 0.845 0.490–1.459
Pathologic type (WHO I vs. II–III) 0.415 0.473 0.380 1.515 0.599–3.830
Chemotherapy (yes vs. no) −0.409 0.484 0.398 0.664 0.257–1.716
Radiation dose (<73.92 vs. ≥73.92 Gy) −0.189 0.437 0.666 0.828 0.352–1.950
GTV‑P (≤46.4 vs. >46.4 mL) 0.901 0.261 0.001 2.463 1.478–4.104
LRFS Age (<50 vs. ≥50 years) 1.768 0.578 0.002 5.857 1.887–18.186
T category (T3 vs. T4) −0.151 0.801 0.851 0.86 0.179–4.133
N category (N0 vs. N1 vs. N2 vs. N3) −0.108 0.249 0.663 0.897 0.551–1.462
Sex (male vs. female) 0.150 0.571 0.793 1.162 0.379–3.557
Pathologic type (WHO I vs. II‑III) 0.355 0.765 0.643 1.426 0.318–6.391
Chemotherapy (yes vs. no) −0.369 0.776 0.634 0.691 0.151–3.165
Radiation dose (<73.92 vs. ≥73.92 Gy) −0.659 1.038 0.525 0.517 0.068–3.956
GTV‑P (≤46.4 vs. >46.4 mL) 1.029 0.520 0.048 2.798 1.010–7.746
DMFS Age (< 50 vs. ≥ 50 years) 0.252 0.281 0.370 1.287 0.741–2.234
T category (T3 vs. T4) 0.559 0.543 0.303 1.749 0.604–5.068
N category (N0 vs. N1 vs. N2 vs. N3) 0.418 0.147 0.005 1.519 1.138–2.027
Sex (male vs. female) −0.132 0.303 0.664 0.877 0.485–1.586
Pathologic type (WHO I vs. II‑III) 0.255 0.525 0.627 1.291 0.461–3.611
Chemotherapy (yes vs. no) −0.178 0.613 0.771 0.837 0.252–2.780
Radiation dose (<73.92 vs. ≥73.92 Gy) −0.024 0.440 0.956 0.976 0.412–2.313
GTV‑P (≤46.4 vs. >46.4 mL) 0.963 0.280 0.001 2.620 1.514–4.534
DFS Age (<50 vs. ≥50 years) 0.535 0.225 0.018 1.708 1.098–2.656
T category (T3 vs. T4) 0.376 0.415 0.365 1.457 0.646–3.286
N category (N0 vs. N1 vs. N2 vs. N3) 0.287 0.118 0.015 1.333 1.057–1.680
Sex (male vs. female) −0.114 0.251 0.649 0.892 0.545–1.459
Pathological type (WHO I vs. II‑III) 0.423 0.401 0.292 1.526 0.695–3.350
Chemotherapy (yes vs. no) −0.337 0.441 0.445 0.714 0.301–1.694
Radiation dose (< 73.92 vs. ≥ 73.92 Gy) −0.105 0.379 0.781 0.900 0.428–1.891
GTV‑P (≤ 46.4 vs. > 46.4 mL) 0.848 0.230 <0.001 2.335 1.487–3.667
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of the above mentioned studies. However, Guo et  al. 
[24] reported GTV-P of 19 mL as an independent prog-
nostic factor for NPC patients undergoing IMRT. Their 
smaller cut-off value may be related to many factors. 
In Guo’s study [24], patients with T3/T4 diseases only 
accounted for 58.2% of all NPC patients, and only 59.7% 
of these patients underwent chemotherapy. Moreover, 
the radiation dose to the primary tumor was 68 Gy, and 
only 1.7% of patients with T3/T4 NPC received a boost 
dose of radiation. However, in our study, we only selected 
patients with T3 and T4 disease, and patients with T4 
disease accounted for 82.1% of the 358 selected patients. 
Approximately 90% of our eligible patients underwent 
chemotherapy, and approximately 70% of them under-
went irradiation at a dose ≥73.92 Gy. Advanced clinical 
stage and intensive radiochemotherapy were presumed 
to be the main reasons for increased cut-off value of 
GTV-P that was associated with tumor relapse or metas-
tasis in our study. In addition, the different cut-off val-
ues of GTV-P were also related to the selected imaging 
tool used for target delineation and tumor heterogene-
ity assessment. Most of the above mentioned researches 
were based on CT images. In our study, CT and MRI 
fused images were predominantly used to delineate the 
target, which improved the accuracy. Furthermore, the 
eventual GTV determined by the same professor of radi-
ology and oncology with 20  years’ working experience 
narrowed the individual evaluation differences for the 
GTV.
This study had several limitations. First, in this retro-
spective analysis, the radiation doses and chemotherapy 
regimens vary among patients. Second, the follow-up 
duration (3–6  years) may be too short to detect NPC 
relapse. Third, the number of patients with T3 disease is 
too small. Therefore, it is necessary to design prospective 
studies to evaluate our findings.
Conclusions
In patients with locally advanced NPC, GTV-P >46.4 mL 
is an independent unfavorable prognostic indicator for 
OS, LRFS, DMFS, and DFS after IMRT. The cut-off val-
ues of GTV-P were 46.4 mL for OS and DFS prediction, 
57.9  mL for LRFS prediction, and 75.4  mL for DMFS 
prediction. The prognostic value of GTV-P (>46.4 mL) is 
superior to T category.
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